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A B S T R A C T   
In this work, the application of various mesoporous silica grades in the preparation of stabilized ternary 
amorphous solid dispersions of Felodipine using hot melt extrusion was explored. We have demonstrated the 
effectiveness of mesoporous silica in these dispersions without the need for any organic solvents i.e., no pre- 
loading or immersion steps required. The physical and chemical properties, release profiles of the prepared 
formulations and the surface concentrations of the various molecular species were investigated in detail. For-
mulations containing 25 wt% and 50 wt% of Felodipine demonstrated enhanced stability and solubility of the 
drug substance compared to its crystalline counterpart. Based on the Higuchi model, ternary formulations 
exhibited a 2-step or 3-step release pattern which can be ascribed to the release of drug molecules from the 
organic polymer matrix and the external silica surface, followed by a release from the silica pore structure. 
According to the Korsmeyer-Peppas model, the release rate and release mechanism are governed by a complex 
quasi-Fickian release mechanism, in which multiple release mechanisms are occurring concurrently and 
consequently. Stability studies indicated that after 6 months storage of all formulation at 30% RH and 20 ◦C, 
Felodipine in all formulations remained stable in its amorphous state except for the formulation comprised of 40 
wt% Syloid AL-1FP with a 50 wt% drug load.   
1. Introduction 
Since up to 90% of new chemical entities and 40% of drugs with 
market approval [1] possess poor aqueous solubility, innovative ap-
proaches are needed to increase the aqueous solubility of identified drug 
candidates and, subsequently, enhance their dissolution/solubility and 
bioavailability [2]. The rendering of a crystalline drug into its amor-
phous form has emerged as one of the most promising approaches [3,4], 
due to its substantial increase in apparent solubility and its superior 
dissolution rate [5]. However, as a result of its thermodynamic insta-
bility, the amorphous form of the pure drug is prone to time dependent 
recrystallisation [6]. Traditionally, the generation of stable amorphous 
solids has been realised through dispersion of the drug into a polymer 
matrix (amorphous solid dispersions (ASDs)), thus inhibiting recrystal-
lisation [2,4,7]. Albeit dependent on molecular interactions between 
constituents and the physicochemical properties of constituents and the 
final product; time-dependent and/or moisture induced phase 
separation are widely reported [6,8,9]. To this end, the use of porous 
silica in the generation of pharmaceutical drug products with enhanced 
physicochemical properties has gained tremendous interest [10,11]. 
Silica – porous or not, is best known for its ability to act as a flow 
enhancer [12–14] or anticaking agent [15]. Owing to its ability to 
incorporate guest molecules into its pore structure (when porous) and/ 
or adsorbed onto its external surface [16], various researchers have 
evidenced the ability of silica to inhibit drug recrystallisation, through 
interfacial interactions with drug molecules such as hydrogen bonding, 
hydrophobic and/or electrostatic interactions, and/or through physical 
restriction of drug molecules located within the pore structure 
[6,16–18]. These formulations possess superior solubility to the crys-
talline drug and increased dissolution rates – a term coined as the spring 
effect. Despite the advantages of porous silica in the generation of ASDs, 
processing technologies have been widely limited to solvent based 
techniques. As drugs of interest typically exhibit poor aqueous solubil-
ity, the deployment of organic solvents during preparation is of 
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particular concern. Additionally, ASDs prepared in this manner were 
often shown to exhibit recrystallisation tendencies upon storage [19], 
result in incomplete release [20]; or recrystallise soon after the initial 
spring effect during in-vitro dissolution studies [6,21], thus restricting 
the use of these drug products mainly to the academic realm with no 
commercialisation to-date. In order to ameliorate some of the observed 
shortcomings, methods such as tuning of the pore structure and/or 
surface modification/functionalisation [17,22] and the incorporation of 
polymeric precipitation inhibitors (PI) [23–26] have been investigated. 
Issues such as drug recrystallisation were seemingly mitigated and/or 
supersaturation maintained. However, in such cases the environmental 
burden and manufacturing related costs, due to the use of organic sol-
vents and the need to operate in batch mode, remain unresolved. The use 
of twin-screw hotmelt extrusion (HME) has gained great attention as an 
environmentally friendly and solventless technique, with proven history 
of commercialised drug products [27,28]. Twin screw extrusion (TSE) as 
a continuous/semi-continuous manufacturing platform lends itself to 
process analytical techniques (PAT) [29], with the capability of scale up 
[7,30]. Nonetheless, to-date only few researchers have utilised TSE/ 
HME as an alternative to earlier methods described, for the preparation 
of amorphous drug products through the use of silica [31–35]. A major 
drawback, previously identified using this approach, is the need for high 
drug loads to allow extrusion without a torque overload [16], which led 
to the incorporation of organic polymers as extrusion aids. In actuality, 
the ability of the polymer to function as a precipitation inhibitor extends 
its use beyond a simple extrusion aid and necessitates its presence in 
such formulations, although, as evidenced in the work of Hanada et al. 
[31], the choice of the PI will significantly affect the dissolution 
performance. 
Hitherto, a fundamental understanding of the loading degree and 
release profile as a result of employing silica grades differing in the 
aforementioned characteristics through HME has not been investigated. 
Thus, the question arises as to whether the addition of said to a con-
ventional organic polymer-drug combination would improve the 
formulation in terms of its critical quality attributes, or in fact prove 
detrimental. Providing critical insights into the underlying mechanism 
behind the observations made, we believe, would enable rational 
material selection and formulation design, tailored to the need of the 
dosage form. If successful, this would serve as a further drive towards 
commercialisation given that a scalable processing technology with 
evidenced commercialisation of output products is utilised. 
To this end, in the current work, we sought to understand the effects 
of three mesoporous silica grades, differing in their particle size, pore 
volume and/or specific surface area in ternary amorphous dispersions 
comprised of the poorly water soluble drug Felodipine and the organic 
polymer Soluplus. As milling or pelletization of extrudates post hotmelt 
extrusion forms an integral step as part of the formulation development 
into final solid dosage forms [36,37], we characterised physical prop-
erties of extrudates post milling and sieving thus allowing for a rational 
understanding of the additive or detrimental effects of the employed 
silica grades in the ternary amorphous solid dispersions. 
2. Materials & methods 
2.1. Materials 
Felodipine form I (FEL) was procured from Baoji Guokang Biotech-
nology, China; Sodium lauryl Sulphate, Acetonitrile, Ortho-phosporic- 
acid and Magnesium chloride were procured from VWR, Ireland; mes-
oporous silicas (MPSI) XDP3050 (SyA), AL-1FP (SyB) and 244FP (SyC) 
were kindly donated by GRACE GmbH & Co. KG, Germany; Soluplus 
(SOL) was donated by BASF, Ireland. 
2.2. Formulation preparation and hotmelt extrusion 
Formulations totalling 45 g with compositions as given in Table 1 
were accurately weighed and placed in plastic containers with at least 
20% headspace. A Stuart General Purpose Rotator (model: STR4) with a 
mixing time of 30 mins, was employed for uniform mixing of the for-
mulations. The twin screw extruder (TSE) comprised of 6 barrels 
(Hybrid TSE ZE 5/12, Three-Tec GmbH, Switzerland), which were 
heated to 160 ◦C. This sample temperature, which lies above the melting 
point of FEL (MP: 141.32 ◦C) and the glass transition temperature of SOL 
(Tg: 76.03 ◦C), was chosen in order to decrease formulation viscosity, 
enable extrusion and promote sorption of API molecules onto the in-
ternal and external surface of the silica grades employed. 
Formulations were manually fed into the extruder, with occasional 
mixing to minimise segregation. HME was undertaken at a screw speed 
of 20 rpm. Extruded formulations were allowed to cool to room tem-
perature, placed in lidless plastic containers and stored in a borosilicate 
chamber over silica gel at room temperature (20 ◦C). These formulations 
were later milled under liquid nitrogen, using a Retsch Mixer Mill 
MM400 (Retsch GmbH, Germany) ranging from 15 to 90 s at 25 Hertz. 
Liquid nitrogen was employed to minimise heating of the sample 
chamber and subsequent phase separation due to the imparted kinetic 
energy during milling. It was assumed that milling times employed were 
insufficient to induce phase transformations of residual crystalline 
content (if present), this assumption was verified by undertaking DSC 
studies on selected samples before and after milling (results not shown). 
Milled samples were sieved through a 300 μm sieve and a fraction was 
stored in a borosilicate chamber equilibrated to 33% relative humidity 
(RH) by using a saturated magnesium chloride solution for stability 
studies, whilst the remainder was returned to the borosilicate chamber 
containing silica gel. 
2.3. Thermogravimetric analysis (TGA) 
TGA analysis of FEL and SOL were undertaken (n = 3) using a TGA- 
4000 thermogravimetric analyser (Perkin-Elmer, United Kingdom) at a 
heating rate of 10 ◦C/min. Nitrogen was used with 30 mL/min as in-
strument and balance purge gas. The recorded mass at the temperature 
point of 120 ◦C was taken as the 100% mass in order to minimise the 
contribution of residual moisture/solvent; the degradation onset 
Table 1 
Constituent composition of prepared formulations. (A) represents the 25 wt% 
drug load formulation and (B) represents the 50 wt% drug load formulation.  










FEL-SOL (A) 25 75 0 0 0 
SyA − 20 wt% 
(A) 
25 55 20 0 0 
SyB − 20 wt% 
(A) 
25 55 0 20 0 
SyC − 20 wt% 
(A) 
25 55 0 0 20 
SyA − 40 wt% 
(A) 
25 35 40 0 0 
SyB − 40 wt% 
(A) 
25 35 0 40 0 
SyC − 40 wt% 
(A) 
25 35 0 0 40 
FEL-SOL (B) 50 50 0 0 0 
SyA − 20 wt% 
(B) 
50 30 20 0 0 
SyB − 20 wt% 
(B) 
50 30 0 20 0 
SyC − 20 wt% 
(B) 
50 30 0 0 20 
SyA − 40 wt% 
(B) 
50 10 40 0 0 
SyB − 40 wt% 
(B) 
50 10 0 40 0 
SyC − 40 wt% 
(B) 
50 10 0 0 40  
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temperature was taken as the temperature point at which more than 1% 
weight loss occurred. 
2.4. Differential scanning calorimetry (DSC) 
Conventional DSC was undertaken in triplicates on FEL and during 
the stability studies of prepared formulations for the determination of 
melt endotherms and recyrstallisation peaks, using a Perkin–Elmer Pyris 
1 Differential Scanning Calorimeter equipped with a refrigerated cool-
ing accessory (Perkin-Elmer, United Kingdom). Instrument calibration 
was performed using high purity indium and lead standards. Samples of 
approximately 5 mg were weighed in open aluminium pans. DSC was 
performed under a nitrogen gas atmosphere, at a gas flow rate of 30 mL/ 
min. Samples in open aluminium pans were ramped from 10 ◦C to 
160 ◦C at a heating rate of 20 ◦C/min. 
StepScan DSC in triplicates, for the determination of glass transi-
tions/melt endotherms/recrystallisation exotherms, was undertaken on 
the extruded formulations post milling and sieving within one week of 
preparation (in the first heating run), in-situ prepared amorphous dis-
persions in the DSC and separately for SOL and FEL, using a Pyris 1 
differential scanning calorimeter. This methodology was employed for 
accuracy and for enhanced separation of overlapping events. Samples 
between 5 mg and 6 mg in open aluminium pans were analysed in a 
nitrogen gas atmosphere (30 mL/min) with the following StepScan 
procedure: Heating steps of 2 ◦C at a heating rate of 20 ◦C/min and 
isothermal steps of 1 min with a criteria of 0.01. The Cp (reversing 
signal) and non-reversing signals were obtained using the StepScan 
software provided by Perkin–Elmer and reported are the reversing sig-
nals for the determination of respective Tgs of prepared formulations. 
The use of open aluminium pans was employed to minimise pan 
movement and deformations as a result of pressure build up due to the 
evolution of sorbed moisture. In doing so, phase transition distortions 
and artifacts were minimised, which were otherwise evident when 
closed pans or pierced pans were used. As the StepScan methodology 
utilises a criterion before the next heating step is initiated, temperature 
equilibrium across the sample during measurements was ensured. Tgs of 
FEL and SOL and in-situ DSC prepared amorphous dispersions were 
determined following a heat-cool-3 min isothermal hold-StepScan cycle. 
The Tgs reported herein are the half extrapolated heat capacity 
temperatures. 
The theoretical glass transition of formulation mixtures was calcu-
lated using the Gordon-Taylor equation [38]: 
Tgmix =
wFEL × TgFEL + k × wSOL × TgSOL






where Tgmix is the glass transition of the formulation mixture, wFEL and 
wSOL are the weight fractions of the API and organic polymer in 
formulation mixtures (Please note that these were normalised in ternary 
mixtures and reported Tgs were determined by calculating the Tg of a 
binary formulation with the same mass ratio of SOL and FEL only). 
Densities ρFEL and ρSOL are the apparent densities of the amorphous FEL 
prepared via melt quenching and SOL, respectively. TgFEL and TgSOL are 
the glass transitions of FEL and SOL, respectively. Constant k is calcu-
lated from the densities and glass transitions of the drug and organic 
polymer. 
2.5. Powder X-ray diffraction (pXRD) 
X-ray powder diffraction studies of as received materials and sieved 
extrudates were undertaken using a PANalytical Empyrean XRD system 
(PANalytical, the Netherlands) between the range of 1◦–60◦ at 2θ with 
Cu-Kα radiation (λ = 1.5418 Å) at a step size of 0.026◦ and a scanning 
rate of 0.328◦/min. 
2.6. Scanning electron microscopy (SEM) 
The morphology of the pristine silica grades and of extrudates post 
sieving were qualitatively investigated using a high-resolution field- 
emission electron microscope (SEM, Hitachi SU-70) (Hitachi High-Tech 
Co., Japan). To avoid overcharging, samples were coated with gold-
–palladium for 90 s with a 20 mA current. Samples were scanned at 1.5 
or 2.5 kV at a working distance of 15 mm and x1000 magnification. 
2.7. Morphologi G3 
Particle size distributions of the pristine silica grades and prepared 
formulations post sieving were analysed using a Morphologi G3 particle 
characterisation system (Malvern Instruments Limited, United 
Kingdom). Prior to analysis, samples were manually tumbled in their 
respective plastic containers to minimise particle size dependent 
segregation. Individual samples were dry dispersed onto glass plates 
using an automated dispersion unit. Dispersion pressures for individual 
samples were selected as the minimum pressure allowing for dispersion 
of powdered material with minimum aggregation. Imaging of dispersed 
samples was conducted using a combination of a 20× (range: 6.5–420 
μm) and 50× (range: 0.5–40 μm) magnification lens. Morphological 
filtering was utilised to remove residual soft agglomerates and over-
lapping particles. In order to ensure uniformity and repeatability, 
measurement of each material was conducted in triplicate and reported 
values are an average of three measurements. 
2.8. X-ray photon electron spectroscopy (XPS) 
Surface chemical analysis of milled extrudates was undertaken via 
XPS by using a KRATOS AXIS ULTRA (Kratos Analytical, Shimadzu 
Corporation, Japan) with monochromatic Al Kα radiation (hν = 1486.6 
eV, 20 mA, 15 kV) at zero angle of emission (vertical emission) under 
ultrahigh vacuum, on a scan area of approximately 1 mm2. Charge 
correction was undertaken by using the C 1s peak attributed to adven-
titious Carbon (284.8 eV) as charge reference. Each analysis was un-
dertaken in triplicate by taking survey spectra at a pass energy of 160 eV, 
with a step size of 1 eV. Atomic concentrations of the elements in the 
near-surface region were calculated following a Shirley type background 
subtraction and by considering corresponding Scofield atomic sensi-
tivity factors and inelastic mean free path (IMFP) of photoelectrons 
using CasaXPS. 
The relative percentage composition of individual molecular species 
(FEL, SOL, MPSI) present on the surface of milled extrudates were 
estimated by adopting a methodology proposed by Faldt et al. [39] with 
adjustments to the components and elements to be analysed. Briefly, the 
atomic concentration of each element present on the surface of the 
milled extrudates was assumed to be a linear combination of the cor-
responding concentrations in the pure materials. Thus, the surface 
fractional composition of the molecular species was calculated by 
solving a matrix, which is expressed as a system of equations (computed 
from the general Equation (3)), via a least square method. The molecular 
compositions were further converted to percentage mass compositions 
by using the molar mass of the drug and the molar mass of the repeat 
units of SOL and MPSI. 
Insample = I
n
SOL × γSOL + I
n
MPSI × γMPSI + I
n
FEL × γFEL (3)  
where superscript n is a placeholder for Carbon, Nitrogen, Oxygen, 
Chlorine and Silicon and In is the fractional amount of the respective 
atoms quantified via XPS, in the sieved extrudates (denoted as subscript 
“sample”), and the pure materials in their as-received state (denoted as 
subscripts SOL for Soluplus, MPSI for respective mesoporous silica 
grades (measured individually) and FEL for Felodipine). Variables γSOL, 
S. Solomon et al.                                                                                                                                                                                                                                
European Journal of Pharmaceutics and Biopharmaceutics 165 (2021) 244–258
247
γMPSI and γFEL are the unknown fractional surface area coverage of the 
molecular species SOL, MPSI and FEL, respectively. 
2.9. Attenuated fourier transform infrared spectroscopy (aFTIR) 
FTIR spectra were recorded at ambient temperature using a Spec-
trum 100 spectrometer (Perkin-Elmer, United Kingdom) equipped with 
a pressure clamp and an attenuated total reflection (ATR) accessory with 
a ZnSe crystal at wavelengths of 4000–400 cm− 1. Samples of approxi-
mately 2 mg were placed on the crystal with a calibrated lever and 128 
scans were collected at a resolution of 4.00 cm− 1. 
2.10. Dissolution 
The dissolution studies were performed under sink condition (in 
triplicates) using a USP II apparatus with a paddle rotation speed of 50 
rpm for 180 min. Formulations containing 30 mg of FEL were added to 
each dissolution vessel comprised of 600 mL dissolution media (phos-
phate buffer and 1% SLS) at a pH of 6.8, which was equilibrated to 37 ±
0.5 ◦C. 5 mL samples were collected from the media and filtered using 
0.2 μm PTFE filters at specified time intervals, with equivalent 
replacement of the withdrawn volume with fresh dissolution media. 
Felodipine present in the filtered samples were determined via HPLC- 
UV. 
Data analysis of the release data was undertaken by utilising both 
model independent and model dependent approaches. The model in-
dependent approach employed herein is the dissolution efficiency (DE) 






× 100 (4)  
where DE is the area under the curve at specific time points, t, of interest, 
expressed as a percentage of the area at complete dissolution (y100) at 
Fig. 1. SEM micrographs of milled extrudates after passage through a 300 um sieve. Fig. 1a & b represent binary dispersions of FEL-SOL and FEL-SOL at 25 & 50 wt% 
drug load respectively; Fig. 1c, f & i represent as-received SyA, SyB and & SyC, respectively; 1d, 1g & 1j are representative SEM micrographs of ternary dispersions 
containing 20 wt% SyA, SyB and SyC respectively; 1e, 1h & 1k are representative SEM micrographs of ternary dispersions containing 40 wt% SyA, SyB and SyC, 
respectively. 
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the same time point. Y denotes the percentage of dissolved product at 
time t; in this case, t1 was set to 0, the onset of the dissolution 
experiment. 
For model dependent data analysis, the Higuchi model and the 
Korsmeyer-Peppas model were considered. The former model was cho-
sen due to its ability to distinguish between different release mecha-
nisms and the latter due to its relevance in modelling release kinetics 
from insoluble matrices such as the formulations in which MPSIs were 
employed. The Korsmeyer-Peppas model [41] is represented by Eq. (5) 
and the Higuchi model [42] is represented by Eq. (6). 
Mt
M∞
= kKP × tn (5)  





where Mt/M∞ represents the drug fraction dissolved at time, t, and k and 
n are the kinetic constants and the release exponent, respectively. The 
values of n derived herein, were used to define the release mechanism i. 
e. n = 1 signifies a zero order release; n = 0.43 signifies drug release via 
Fickian diffusion; 0.43 < n < 0.85 signifies drug release through 
anomalous diffusion with associated swelling or stresses; at n greater 
than 0.85, Case II transport is expected. 
2.11. HPLC-UV analysis and quantification 
HPLC quantification of Felodipine present in the filtered samples 
from the dissolution studies, was performed with an Agilent 1260 In-
finity Series system (Agilent Technologies, Germany) equipped with a 
G1311B 1260 quaternary pump, G1329B 1260 autosampler, vacuum 
degasser and G1316A 1260 temperature-controlled column compart-
ment maintained at 40 ◦C. The mobile phase consisted of solvents A: 
75% (v/v) acetonitrile and B: 25% (v/v) ortho-phosphoric acid (0.1% v/ 
v). A Kromasil C18 5 μm, 4.6 d 250 mm column (MZ-Analysentechnik 
GmbH, Germany) was used at a flow rate of 1 mL/min. An isocratic 
(total run time 15 min) was used for the separation of Felodipine. 
Typical injection volume was 10 μL. Felodipine was detected at a 
retention time equivalent to 2.54 min at a wavelength of 205 nm. 
2.12. Apparent particle density 
Apparent particle densities (ρapp) of milled extrudates, FEL and SOL 
were measured using a helium gas pycnometer (10 cycles i.e. 10 
consecutive measurements) (AccuPyc 1330, Micrometrics, USA). 
2.13. Stability 
Stability studies were undertaken by exposing the samples to a 
relative humidity of 30% RH at 20 ◦C for a period of 6 months, after 
which pXRD and DSC analyses were undertaken. 
3. Results & discussion 
3.1. Hotmelt extrusion processing temperature 
To determine the upper limit of the allowable processing tempera-
ture at which no degradation occurs, TGA analysis was undertaken. 
From the TGA analysis (Supplementary data), the degradation point at 
which more than 1% weight loss post loss of unbound residual solvent/ 
moisture occurs for the organic compounds lies at 266.53 ◦C for SOL and 
217.46 ◦C for FEL. From preliminary extrusion experiments at 50 wt% 
drug load and 40 wt% MPSI content, we determined that 160 ◦C was the 
minimum temperature required to maintain extrusion below the upper 
torque limit. To rule out possible degradation associated with prolonged 
exposure at this processing temperature, isothermal studies were un-
dertaken in which the neat drug and organic polymer were individually 
exposed to 160 ◦C for 10 mins, which was in excess of the residence time 
of formulations within the extruder. For SOL and FEL, the associated 
weight loss post 10 mins isothermal hold at 160 ◦C were less than 0.2%, 
which was deemed acceptable for processing. 
3.2. Particle morphology, physical state and surface chemical species 
3.2.1. Particle size, morphology and pore structure 
The binary formulations of FEL-SOL at 25% drug load (FEL-SOL (A)) 
and 50% drug load (FEL-SOL (B)) were collected as clumps and thus 
required milling post extrusion. SEM micrographs of the extrudates post 
cryogenic milling and sieving through a 300 μm sieve are depicted in 
Fig. 1a and 1b. At the spatial resolution employed, both formulations 
present irregular shapes with a smooth surface with Dv50s of these 
milled extrudates at low and high drug load (Table 2), of 79.7 μm and 
68.95 μm, respectively. Similar to the binary FEL-SOL formulations, 
extrudates at both low and high drug loads containing 20 wt% of the 
MPSI grades employed, were collected as strands. This was also the case 
for formulations containing 40 wt% SyB. In contrast, formulations 
containing 40 wt% SyA or SyC were collected as powders. Thus, minimal 
milling times were necessary (<20 s) to obtain sieve fractions below 300 
μm for these formulations. 
Resultant SEM micrographs of the milled ternary extrudates and the 
different as-received MPSI grades are depicted in Fig. 1c–k. Note that the 
micrographs of the formulations are representative of the morphological 
properties at both 25% and 50% drug loads. As observed in the SEM 
micrographs and from the particle size distributions measurements, all 
milled ternary formulations result in particles with a wider span and 
larger Dv50 than the MPSI grades in their as-received state. 
The morphology of formulations containing 20 wt% SyA are similar 
to those of the binary FEL-SOL formulations, indicative of particles with 
a predominant surface concentration of FEL and/or SOL. SEM micro-
graphs of formulations containing 40 wt% SyA (Fig. 1e) depict hard 
agglomerates with rough surfaces with discernible SyA particles pre-
sumably fused together by FEL and/or SOL along with regions of un-
coated SyA surfaces. 
SEM micrographs of formulations containing 20 wt% or 40 wt% SyB 
(Fig. 1g and h) display surface textures identical to those of the binary 
FEL-SOL formulations, thus pointing to a predominant surface concen-
tration of FEL and/or SOL. Similar characteristics are observed in the 
formulations containing 20 wt% SyC (Fig. 1j). In contrast, formulations 
containing 40 wt% SyC (Fig. 1k) depict particles with a vastly different 
surface texture. Unlike the smooth surface texture observed in the 20 wt 
% SyC formulation, a rough surface comprised of a layer of densely 
packed particles of similar Dv50s to that of as-received SyC is found on 
the surface of these hard agglomerates. 
Table 2 
Physical properties of MPSI (as received) and milled extrudates post passage 
through a 300 μm sieve.  
Material/Formulation Dv10 Dv50 Dv90 Span 
SyA 29.80 51.69 77.11 0.92 
SyB 4.58 10.03 15.99 1.14 
SyC 1.72 3.43 5.87 1.21 
FEL-SOL (A) 18.56 79.70 205.90 2.35 
SyA − 20 wt% (A) 14.63 67.31 203.80 2.81 
SyB − 20 wt% (A) 24.52 81.43 236.00 2.60 
SyC − 20 wt% (A) 25.80 94.52 258.30 2.46 
SyA − 40 wt% (A) 18.79 54.26 124.00 1.94 
SyB − 40 wt% (A) 20.33 74.22 226.70 2.78 
SyC − 40 wt% (A) 26.48 88.87 184.50 1.78 
FEL-SOL - (B) 18.17 68.95 235.70 3.15 
SyA − 20 wt% (B) 20.34 56.76 211.40 3.37 
SyB − 20 wt% (B) 24.25 85.16 274.10 2.93 
SyC − 20 wt% (B) 19.40 66.08 208.90 2.87 
SyA − 40 wt% (B) 19.39 55.24 139.00 2.17 
SyB − 40 wt% (B) 18.57 67.18 275.80 3.83 
SyC − 40 wt% (B) 16.30 84.69 231.40 2.54  
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3.2.2. Surface chemical species identification via XPS 
Similar to the observations made in the SEM micrographs, the sur-
face spatial distributions of SOL, FEL and the respective MPSI grades on 
the milled formulations were estimated via wide scan XPS. The sampling 
depth of XPS is typically up to 10 nm, due to strong attenuation of 
photoelectrons by passage through the sample of interest [43,44], 
enabling the high surface sensitivity of this technique. 
According to the XPS survey spectra analysis of extruded formula-
tions (Fig. 2), the binary FEL-SOL formulation at a 25 wt% drug load 
presents a FEL surface concentration of 18.62 wt% ±0.64. At the same 
drug load, a 20 wt% concentration of MPSI, results in a lower FEL sur-
face concentration in the SyA-20 wt% formulation (15.99 wt% ± 0.99) 
and slightly higher surface concentrations in the SyB-20 wt% (19.53 wt 
% ±0.71) and SyC-20 wt% (18.69 wt% ±1.59) formulations. Interest-
ingly, we observe a relatively high surface concentration of SyA (35.68 
wt% ±1.63), whilst negligible surface concentrations of SyB (2.78 wt% 
±0.99) and SyC (5.70 wt% ±0.59) are observed for corresponding for-
mulations. At a 40 wt% MPSI content for the same drug load, the for-
mulations containing SyA and SyC reveal relatively higher surface 
concentrations of FEL i.e. 29.16 wt% ±1.63 and 37.29 wt% ±0.54, 
respectively. 
However, the respective MPSI surface concentration also increases 
significantly i.e. 60.13 wt% ±0.91 in the case of SyA and 62.24 wt% 
±0.79 in the case of SyC. Due to the penetration depth realised by XPS, 
we cannot ascertain if contributions to the XPS signal are a result of the 
top most layer of a single species (i.e. FEL multilayers) of a thickness 
beyond the penetration depth of XPS, or if surface concentrations real-
ised herein are a result of monomolecular to multilayer dispersions of 
FEL molecules with subsequent layers differing in the molecular species 
and thus contributing to the signal. The modelling approach utilised 
herein assumes surface layers of a thickness equating at a minimum to 
that of the XPS probing depth [39]. Given the molecular dimensions of a 
single FEL molecule (1.34 nm × 1.21 nm along its largest molecular 
dimensions [45]) and its recorded surface concentrations, it stands to 
reason that regions of FEL multilayers (i.e. FEL-FEL clusters) exist and 
reported herein are the surface to near-surface concentrations within the 
probing zone. Nonetheless, we would like to highlight the earlier SEM 
micrographs of 40 wt% SyC, which display particles seemingly coated 
with SyC. Thus, the survey spectra serve as direct evidence of the earlier 
observations made, with the addition that these coatings consist of FEL 
and SyC. The surface concentration of SOL, which amounts to 10.71 wt 
% ±2.53 in the case of SyA, is nearly non-existent for the SyC formu-
lation (0.47 wt% ±0.26). In contrast, the formulation containing 40 wt% 
SyB at a 25% drug load, display FEL, SOL and SyB surface concentrations 
of 20.26 wt% ±0.83, 74.12 wt% ±0.66 and 5.62 wt% ±0.62, respec-
tively. As observed in Table 3, SyB, despite having the highest specific 
surface area, exhibits the lowest pore size and pore volume. 
In the work of Liu et al., it was shown that with a decrease in pore size 
the loading of adsorbates into the pore structure becomes increasingly 
impeded [47]. Given the small pore size of SyB (3 nm) the internal 
surface area is highly inaccessible and prone to pore blockage in com-
parison to SyA (25 nm) and SyC (17 nm). Hespeler et al., who investi-
gated loading of Rutin via solvent evaporation onto different MPSI 
grades, such as the MPSI grades employed in the current study, observed 
that Rutin molecules adsorbed onto SyB crystallised at the external 
surface resulting in the formation of agglomerates and attributed these 
findings to the smaller pore size of SyB [46]. 
The dynamic viscosities of the polymer and the drug are also 
important. Hanada et al. reported that spreading of polymers employed 
in their research was dictated by the polymer’s dynamic viscosity and 
found that spreading across the MPSI surface improved with a decrease 
in the complex viscosity of the polymer [31]. We content that the high 
surface MPSI concentrations and low SOL surface concentrations 
observed for SyA-40 wt% and SyC-40 wt% are due to a combination of 
the following factors. The larger pore sizes of SyA and SyC in comparison 
to SyB may facilitate sorption of the drug into the pore structure more 
readily. Additionally, polymer spreading may be region specific and may 
occur more slowly (due to its higher dynamic viscosity [48]) than the 
corresponding dispersion of the drug onto the MPSI surface. From these 
observations, the bulk density of the MPSI particles appears to play a 
critical role by limiting the extent of spreading of the polymer/drug to 
particles within close proximity (albeit counteracted by the dynamic 
viscosity of individual adsorbates and adsorbate mixtures). The bulk 
density appears lowest for SyC and highest for SyB, and unsurprisingly, 
























































































































Fig. 2. Surface chemical composition of milled extrudates post passage through a 300 μm sieve (Mean ± SD, n = 3).  
Table 3 


















– – – – 
SOL 1.192 ±
0.003 
– – – – 
SyA – 0.27 1.8* 25* 320* 
SyB – 0.57 0.4* 3* 700* 
SyC – 0.06 1.6* 17* 330*  
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concentration, and the lowest and highest SOL surface concentration, 
respectively, in the 40 wt% MPSI formulations. 
Similar trends are generally observed in the 50 wt% drug load for-
mulations. As a result of the high wt% of FEL employed in these for-
mulations, a significant increase in FEL surface concentration is 
observed alongside a decrease in the surface MPSI concentration in 
comparison to corresponding MPSI loads in the low drug load 
formulations. 
We also briefly discuss the favourable sites of particle fragmentation 
during milling of extrudates. As outlined in the works of Meier et al. the 
deformation of materials is dictated by their mechanical properties such 
as hardness, elasticity/plasticity and fracture toughness [49]. As extru-
dates were milled at cryogenic temperatures, which are well below the 
glass transition of the amorphous materials, deformation of particles 
resulting in particle size reduction are predominantly realised by brittle 
fracture [50] through comminution (i.e. through the extrudate strands) 
and attrition (i.e. at edges and corners). As extrusion was undertaken at 
160 ◦C, which lies significantly above the glass transition of the polymer 
and the melting point of the API, in the case of the binary mixtures 
dispersion of the drug from its bulk phase into the polymer matrix occurs 
albeit limited by its solubility and rate limited by the polymer’s viscosity 
[51] at the processing conditions employed. Of course, this is further 
complicated by the presence of MPSI, and further governed by the 
structural properties, surface chemistry and bulk properties of the MPSI 
grades employed. As such, the resultant dispersions may exhibit polymer 
rich and drug rich phases thus resulting in regional variations in hard-
ness. We argue, however, that comminution of MPSI particles (not 
withstanding attrition and other structural factors) is less favourable to 
fracture (especially at the low milling times employed) due to the 
covalently bound siloxane infrastructure responsible for the makeup of 
MPSI primary particles. 
3.2.3. Physical state investigations via PXRD and DSC 
To investigate the physical state of the drug and confirm the absence 
or presence of the crystallinity within milled formulations, PXRD and 
DSC analyses was undertaken. As observed in Fig. 3, all milled extru-
dates appear amorphous, given the absence of Bragg’s peaks charac-
teristic to FEL, which instead exhibit halo diffraction patterns. DSC 
thermograms of these milled extrudates are devoid of melting endo-
therms, further confirming the amorphicity of FEL in milled extrudates. 
Natalja et al. utilised DSC in order to estimate the distribution of 
Ibuprofen (IBU) in ternary amorphous dispersions containing MPSI and 
SOL [34]. In their work, they utilised the Flory-Fox equation to compute 
theoretical Tgs of binary IBU-SOL mixtures and compared these to 
experimentally derived Tgs. Tgs of the ternary extrudates containing 
MPSI were also included and they concluded that the increase in 
observed Tgs was a result of monomolecular loading of IBU onto and/or 
into the employed MPSI. Similarly to their work, we utilised the Gordon- 
Taylor (G-T) equation to compute theoretically derived Tg values of 
binary FEL-SOL mixture and evaluated the proximity of predicted Tgs to 
those obtained from melt quenched FEL-SOL dispersions prepared in- 
situ in the DSC. The G-T equation is based on the assumption of ideal 
volume additivity at Tg, a linear change in volume with temperature and 
an ideal mixing behaviour, whereby polymer–polymer, API-polymer 
and API-API interactions are of equal magnitude [38,52]. As a result, 
positive or negative deviations are attributed respectively to stronger or 
weaker hetero interactions in comparison to homo interactions of 
components in the dispersions or phase inhomogeneity. These 
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Sy - 0 wt%
Fig. 3. DSC thermograms of prepared formulations post milling immediately after extrusion.  
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interactions ultimately lead to a decrease (stronger hetero interactions) 
or increase (weaker hetero interactions/phase inhomogeneity) in the 
free volume than the ideal volume additivity assumed in the G-T equa-
tion. As seen in Fig. 4, negative deviations in experimental Tg values of 
binary FEL-SOL, prepared in-situ in the DSC (<9 ◦C), from predicted G-T 
Tg values are observed. Given the stronger hydrogen bonding in-
teractions observed in the aFTIR spectra between FEL and SOL, positive 
deviations were expected. 
Nonetheless, Lu et al. reported similar observations to those made in 
the current research contribution for binary FEL-SOL solid dispersions 
[53]. As the current formulations were prepared in the DSC in-situ at 
160 ◦C, under a Nitrogen atmosphere followed by a heating cycle to 
determine Tgs, effects of moisture on lowering of Tg are negligible. 
Similarly to the aFTIR observations for the extruded formulations, aFTIR 
spectra (results not shown) of these formulations present N-H stretch 
shoulders (albeit to varying degrees) attributed to the presence of FEL- 
FEL hydrogen bonded phases, indicative of a non-homogenous 
mixture leading to an increase in the free volume and a consequently 
lower Tg. 
Stronger negative deviations are observed (see Fig. 4) in the extruded 
binary FEL-SOL milled extrudates, pointing to stronger phase hetero-
geneity, albeit more exacerbated in the 50 wt% drug load which is a 
result of a more pronounced presence of an FEL-FEL hydrogen bonded 
phase. A 20 wt% addition of SyB or SyC also results in negative Tg de-
viations from the predicted G-T Tgs. Despite having a lower SOL content 
in comparison to the binary FEL-SOL dispersion, these formulations 
present Tgs which are up to 2.4 ◦C higher than the Tg of the milled bi-
nary FEL-SOL extrudate at the same drug load. However, formulations 
containing 20 wt% of SyA, 40 wt% SyA and 40 wt% SyC result not only 
in higher Tg values than FEL-SOL but also in positive deviations from 
those predicted using the G-T equation. For the 50% drug loads similar 
trends to the 25% drug load formulations are observed. At this point, the 
question arises if the observed increase in Tgs in comparison to FEL-SOL 
is due to MPSI-SOL interactions (e.g. via pore confinement/intermo-
lecular interactions), resulting in decreased polymer mobility, or in fact 
is due to interactions with FEL. Thus binary dispersions of SOL-SyA at 
25 wt%, 50 wt% and 75 wt% SOL content and FEL-SOL-SyA dispersions 
with a 1:1 FEL-SOL ratio at 25 wt%, 50 wt% and 75 wt% SyA content 
were prepared in-situ in the DSC, with subsequent measurement of 
respective Tgs. For the ternary dispersion, this ratio was maintained in 
order to ensure that the observed changes in Tgs could be solely 
attributed to the increase in SyA content. As observed in Fig. 5, the bi-
nary mixture of SOL-SyA shows a negligible increase in Tg (<1◦C) in 
comparison to pure SOL. 
The addition of SyA in the ternary mixture as observed in Fig. 5 re-
sults in an increase in Tg above the predicted G-T Tg, while the Tg at 75 
wt% SyA deviates from the Tg of pure SOL by only 1.09 ◦C. As the 
incorporation of FEL into the SOL matrix proceeds in a time dependent 
manner, limited by the viscosity [54] of and interactions with SOL in the 
presence of MPSI, free drug molecules in direct contact with the MPSI 
surface may form intermolecular interactions resulting in immobilisa-
tion of the drug or are diffused into the pore structure. Indeed, mono-
molecular sorption onto a MPSI surface has been shown to provide no 
contribution to the Tg measurements via DSC due to the highly 
restrictive nature of the interfacial interactions resulting in restricted 
molecular motions of said drug molecules [55]. 
3.3. Solid state and intermolecular interactions via aFTIR 
Complementary to the XPS analysis, the chemical makeup of 
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Tg of pure SOL
50 % API
Tg of pure FEL
SyA - ternary SyB - ternary SyC - ternary FEL-SOL**G-T FEL-SOLFEL-SOL*
Fig. 4. Glass transition of milled extrudates determined from StepScan DSC measurements. *Denotes FEL-SOL Binary formulation prepared via hotmelt extrusion 
**Denotes FEL-SOL binary formulations prepared in-situ in the DSC and are displayed for reference. 












Tg of pure SOL
FEL-SOL (1:1) GT FEL-SOL (1:1)
Fig. 5. Tgs of binary SOL-SyA and ternary FEL-SOL-SyA formulations prepared 
and analysed in-situ in the DSC post melt quenching at 160 ◦C for 3 mins (Mean 
± SD, n = 3). For the ternary formulations the FEL-SOL ratio was kept at a 1:1 
mass ratio and 25 wt%, 50 wt% and 75% SyA were added to the combined FEL- 
SOL mass. The dotted black line represents the Tg of a 1:1 ratio of FEL-SOL 
prepared in-situ under the same condition. The blue solid represents the Tg 
predicted by the Gordon-Taylor equation at a 1:1 FEL-SOL mass ratio. (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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relevant chemical bonds of the pristine materials were analysed via 
aFTIR to probe for hydrogen bonding interactions between the API and 
the inorganic/organic polymers and, qualitatively, to locate drug mol-
ecules within the particles. The latter is based on the theoretical 
calculation of the penetration depth [56] for an aFTIR measurement 
through a ZnSe prism at a 45◦ incidence angle, which may range from 
~0.5 to 2.01 μm (as a function of a frequency ranging from 4000 to 

















FEL MQ SOL SYA SyB SyCFEL
Fig. 6. FTIR spectra of Felodipine Form I (FEL), Felodipine melt quenched via DSC (FEL MQ), Soluplus, Syloid XDP 3050 (SyA), Syloid ALI FP (SyB), Syloid 244 
FP (SyC). 
Fig. 7. FTIR spectra of milled extrudates post passage through a 300 μm sieve.  
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(FEL: RI = 1.57 [57]; MPSI: RI = 1.45 [58]; RI of SOL is not reported but 
assumed to be similar to that of FEL and MPSI). The aFTIR spectra for the 
pristine materials and unary melt quenched Felodipine are presented in 
Fig. 6. Notably, pristine Felodipine displays an N–H stretching peak at 
approximately 3367 cm− 1 and a C–O stretching peak at 1687 cm− 1, 
with a shoulder centred around 1694 cm− 1. The C–O stretching peaks 
are attributed to hydrogen bonded ethyl ester and methyl esters, 
respectively [59]. 
Amorphous FEL melt quenched using DSC in open pan mode presents 
a broad peak in the N–H stretching region, with a maximum located at 
3334 cm− 1 and a feint shoulder centred around 3415 cm− 1. Intermo-
lecular hydrogen bonding of N–H groups with adjacent Felodipine 
molecules have been shown to be stronger than crystalline counterparts 
whereby one of the two carbonyl groups participates in stronger 
hydrogen bonding with a stronger shift to lower wave numbers, whilst 
the other remains unassociated/weakly hydrogen bonded with a shift to 
higher wave numbers [59]. The carbonyl oxygen in the current case 
displays a broadened peak with maxima located at 1679 cm− 1 and 1696 
cm− 1, respectively. 
AFTIR spectrum for SOL displayed several notable peaks, such as a 
broad peak ranging from 3650 to 3200 cm− 1, attributed to an overlap of 
intermolecularly hydrogen bonded hydroxyl groups of its backbone 
[58,60] and stretching vibrations of physiosorbed water; peaks at 1732 
cm− 1 and 1627 cm− 1 are respectively assigned to C–O stretching in the 
ester and the tertiary amide [5,58]. The aFTIR spectra for the different 
MPSI grades present a peak at 1065 cm− 1 and 1047 cm− 1 for SyA 
(identical for SyC) and SyB, respectively, attributed to stretching vi-
brations of siloxane. The observed shift in the case of SyB is attributed to 
an increase in the proportion of silicon sites with non-bridging oxygens 
[61] in the form of Q3 species, with associated silanol groups. Peak 
location of corresponding silanol groups are observed at 970 cm− 1 for 
SyA and SyC and at 946 cm− 1 for SyB. 
The extent and nature of hydrogen bonding of Felodipine molecules 
in hotmelt extruded formulations are presented in Fig. 7. At a 25 wt% 
drug load, the N–H stretch of the Felodipine molecules in the binary 
formulation of FEL and SOL undergoes a stronger bathochromic shift in 
comparison to unary amorphous FEL with a peak maximum at approx-
imately 3293 cm− 1 attributed to strong FEL-SOL hydrogen bonding in-
teractions. A relatively weak shoulder centred around 3329 cm− 1, 
attributed to amorphous FEL-FEL hydrogen bonding interactions. This 
shoulder gains in intensity in the 50–50 FEL-SOL binary mixture. 
The addition of 20 wt% of the different MPSI grades at a 25 wt% drug 
load presents similar features to the binary formulation (25 wt% API), 
such as a peak maximum at approximately 3293 cm− 1 and a shoulder 
centred around 3329 cm− 1. At 40 wt% of SyA or SyC, the shoulder 
previously centred at approximately 3329 cm− 1 experiences a syn-
chrotronic shift to approximately 3337 cm− 1 and manifests as a peak 
(with a more prominent intensity) for the formulation containing SyC, 
and a feint shoulder centred around 3293 cm− 1 in the case of SyA. In 
contrast, SyB at 40 wt% retains spectral features observed in the 25% 
binary formulation. The ternary mixtures at a 50 wt% drug load and 20 
wt% SyA and SyB indicate a higher intensity of the peak located at 
approximately 3337 cm− 1 relative to that located at 3293 cm− 1; the 
reverse is observed for the same formulation containing SyC. At 40 wt% 
MPSI content, a single peak, with a peak maximum at approximately 
3337 cm− 1 attributed to clusters of FEL-FEL hydrogen bonding in-
teractions is observed for all MPSI grades. 
To elucidate the observed trend and confirm the presence of 
hydrogen bonded amorphous FEL-FEL clusters, we turn to the spectra 
bands in the regions between 1630 cm− 1 and 1760 cm− 1 (Fig. 7 – area 
shaded in gray), which contain C–O stretching vibrations of the esters 
of SOL and FEL. As there is no overlap between the ester C–O vibrations 
Fig. 8. Dissolution profiles of pristine FEL and milled extrudates post passage through a 300 μm sieve (Mean ± SD, n = 3). *Indicates 25 wt% drug load and 
**indicates 50 wt% drug loads. 
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of amorphous FEL (peak maxima at 1679 cm− 1 and 1696 cm− 1) and SOL 
(peak maximum at 1732 cm− 1), potential hydrogen bonding in-
teractions, complementary to the N–H stretching vibrations, can be 
discerned. At a 25 wt% drug load, the binary mixture reveals a syn-
chrotronic shift for C–O stretch vibrations attributed to amorphous 
Felodipine with a single peak maximum located at 1696 cm− 1. In 
conjunction with the observed N–H stretch, this indicates that the 
observed hydrogen bonding interactions are, primarily, with segments 
from the polymer, in which the carbonyl oxygens in the FEL molecules 
are unassociated/weakly associated. The location and peak shape of the 
C–O stretch attributed to SOL appears to remain unaltered (peak 
maxima at approximately 1733 cm− 1) in comparison to pristine SOL. 
Due to overlapping vibrations, no useful conclusions can be drawn for 
the stretching vibrations of the tertiary amide attributed to SOL. The 
same outlined trends are observed for stretching vibrations, comprising 
20 wt% of the different MPSI grades at a 25 wt% drug load. At 40 wt% of 
MPSI content in the 25 wt% drug loads, formulations comprising SyA 
and SyC corroborate earlier observations made in the N–H stretching 
region and are indicative of an elevated presence of amorphous 
hydrogen bonded FEL-FEL clusters relative to those bonded to dissimilar 
moieties. Specifically, in the SyC-40 wt% formulation, the peak 
maximum is located at 1682 cm− 1 with a shoulder centred around 1696 
cm− 1. In the SyA-40 formulation C–O stretching vibrations display a 
peak maximum at 1698 cm− 1 and a feint shoulder peak at 1686 cm− 1. 
The SyB-40 formulation displays only a single peak attributed to C–O 
ester stretching vibrations, located at 1697 cm− 1, indicative of a minor 
presence of FEL–FEL hydrogen bonding interactions. Similar observa-
tions were made in the 50% drug loading formulations, albeit with 
spectra bands indicating a significant presence of FEL–FEL hydrogen 
bonding interactions between FEL molecules clusters corroborating 
findings in the N–H stretching region and thus are not further discussed. 
Generally, no definite conclusions could be drawn regarding Silanol 
related hydrogen bonding, due to the heavy overlap in the O–H bending 
vibration frequencies of this group. 
In light of the trends observed thus far, several key observations are 
highlighted which complement observations from the preceding section. 
Firstly, in the cases of SyA and SyC the peak intensity ratios of FEL and 
SOL are markedly reduced across all frequencies, and diminish with 
increasing percentage composition of the two MPSI grades, whilst 
characteristic MPSI peaks gain in intensity (please refer to the blue 
shaded area in Fig. 7). Similar observations have been made by other 
researchers for various MPSI grades, with the conclusion that the 
reduction in peak intensities may be a result of adsorption into the MPSI 
matrix [32,62,63]. However, given the particle size of the milled 
extrudates and the particle size of the as-received MPSI grades, it is 
probable that FEL is located in the interior of the extrudates alongside a 
presence in the pore structure of primary MPSI particles. This observa-
tion is unique to SyA and SyC however and overlapping FEL/SOL peak 
intensities remain prominent in all formulations containing SyB. It 
should be noted that drug loading was a fixed constant at either 25 wt% 
or 50 wt% thus allowing for a qualitative comparison of encapsulation 
efficiencies between the different MPSI grades at a given drug load. 
Additionally, the distinct presence of FEL-FEL hydrogen bonded clusters 
indicate that the FEL surface concentrations observed during XPS mea-
surements exist as multilayers. 
Characteristic peak intensities of SOL are almost completely absent 
in SyA-40 wt% and SyC-40 wt% formulations at low and high drug 
loading, which corroborates our earlier findings. From our observations 
thus far, the importance of SOL lies in its interaction with FEL molecules 
not monomolecularly dispersed or located within the pore structure of 
the employed MPSI grades and may shed insight into the elevated 
presence of FEL-FEL hydrogen bonding interactions, especially in the 
case of formulations comprising 50 wt% drug loading at 40 wt% MPSI. 
3.4. Dissolution behaviour 
The release profiles of the various formulations are presented in 
Fig. 8. To allow for an interpretation and comparison of the dissolution 
profiles, a model independent approach was employed, by calculating 
dissolution efficiencies (DE) at two time intervals (DE9min and 
DE14.5min). The cumulative amount of drug released (Q) at three time 
points of the dissolution experiment (Q9min, Q14.5min and Q180min) are 
also reported. To elucidate the underlying mechanism of drug release 
from the formulations, the Korsmeyer-Peppas model, which exhibits 
validity for the first 60% of drug release, was utilised along with a plot of 
Higuchi profiles for the ternary amorphous dispersions. According to 
Table 4, the binary mixture of FEL-SOL at a 25 wt% drug load, shows a 
release of 78.86% within 3 min and the dissolution end point, with a 
100% release is attained after 14.5 min. As a result, this formulation 
presents the highest dissolution efficiency, with a DE of 79.51% at 9 min 
and 86.94% at 14.5 min. Based on the Korsmeyer-Peppas model, we find 
that the release mechanism is predominantly governed by non-Fickian 
diffusion, with associated polymer chain relaxation mechanisms. In 
contrast, a 20 wt% addition of the different MPSI grades for the low drug 
load formulation results in a decrease in the Q14.5min and DE14.5min. 
As observed in Table 4, this is most pronounced for the formulation 
containing SyA, with a Q14.5min and DE14.5min of 45.89% and 39.84%, 
respectively. From the DSC studies, we note that this formulation ex-
periences an exceptionally high Tg value, attributed to monomolecular 
loading onto the MPSI surface and thus a low concentration of FEL is 
located in the SOL matrix. We also note a relatively high surface con-
centration of SOL from the XPS studies with the lowest surface con-
centrations of FEL (15.99 wt%) of all formulations under investigation. 
As a result, SOL exhibits a retarding effect on the release of FEL, by 
acting as a barrier, and thus imparting a sustained release character. 
Formulations containing 20 wt% SyB and SyC at the same drug load on 
the other hand exhibit significantly higher Q14.5min and DE14.5min in 
comparison to SyA. Based on our DSC and XPS results, we attribute these 
findings to the location of FEL, which is predominantly within the 
polymer matrix, which in turn exhibits significant surface enrichment at 
the near-surface to surface region of these formulations. Interestingly, 
addition of 40 wt% MPSI results in vastly different Q14.5min and 
DE14.5min. A 40 wt% addition of SyA at the low drug load exhibits a 
Q14.5min of 98.05% and a DE14.5min of 84.78% – a result rivalling that of 
Table 4 
Cumulative drug release and dissolution efficiency of milled extrudates. *Represents formulations with a 25% drug load; and ** represents formulations with a 50% 
drug load.  
Formulation Cumulative drug released (%) Dissolution efficiency (%) Korsmeyer-Peppas 
- Q9 min Q14.5 min Q180 min DE9 min DE14.5 min n 
FEL 15.18 16.4 26.91 11.3 13 0.22 
FEL-SOL 97.6*, 62.21** 100.58*, 64.61** 100.56*, 93.67** 79.51*, 56.39** 86.94*, 60.17** 0.54* , 0.2** 
SyA − 20 wt% 44.48*, 57.35** 45.89*, 59.34** 99.12*, 97.72** 36.57*, 49.99** 39.84*, 54.41** 0.23* , 0.22** 
SyB − 20 wt% 85.61*, 53.48** 92.22*, 54.07** 101.48*, 78.77** 65.47*, 48.73** 74.36*, 51.08** 0.34* , 0.10** 
SyC − 20 wt% 78.75*, 41.48** 83.24*, 41.58** 90.74*, 55.33** 65.25*, 38.58** 71.22*, 40.03** 0.40* , 0.09** 
SyA − 40 wt% 96.33*, 47** 98.05*, 43.94** 99.53*, 101.3** 77.19*, 39.78** 84.78*, 41.63** 0.40* , 0.15** 
SyB − 40 wt% 39.49*, 42.43** 43.95*, 44.53** 93.01*, 65.16** 32.28*, 39.2** 35.86*, 41.53** 0.24* , 0.11** 
SyC − 40 wt% 64.00*, 50.03** 68.3*, 52.42** 92.96*, 88.67** 55.81*, 44.49** 59.73*, 48.04** 0.19* , 0.16**  
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the binary FEL-SOL formulation for the same drug load. Based on XPS 
analysis, the surface concentration of SyA is significantly high (60.13 wt 
%) along with a relatively high surface concentration of FEL (29.16 wt 
%). As indicated by DSC analysis, the majority of FEL is located at the 
MPSI interface. As a result, drug release is governed through Fickian 
diffusion. This is supported by the Korsmeyer-Peppas model, which in-
dicates a near-Fickian diffusion process. In the case of SyB 40 wt% the 
drug release experiences significant impairment, giving a Q14.5min of 
43.95% and a DE14.5min of 35.86%. Based on the earlier character-
isations, we conclude that FEL is located predominantly in the SOL 
matrix, and drug release is governed by SOL and the SOL content 
present. 
Of interest is the drug release from the formulation containing 40 wt 
% SyC. Based on the SEM micrographs and XPS analysis, this formula-
tion consists of hard agglomerates with predominant surface enrichment 
of SyC and FEL. The Q14.5min and DE14.5min are 68.3% and 59.73%, 
respectively. These results indicate a retarding effect of the drug release 
rate with an increase in SyC wt% at this drug load. We attribute these 
observations to the increase in surface coverage of FEL (likely existent in 
multilayers, based on aFTIR spectra), which may impart a hydrophobic 
character and a retarded release rate. 
An increase in the drug load to 50 wt% generally results in retar-
dation of the Q14.5min and DE14.5min for all formulations. At the extreme, 
this results in Q14.5min ranging from 43.94% − 52.42% and DE14.5min 
ranging from 41.63% − 48.04%. The retardation is most pronounced for 
formulations containing 40 wt% SyB. These formulations display the 
highest surface concentrations of FEL, as observed via XPS, which exist 
as hydrogen bonded FEL-FEL amorphous clusters as observed via aFTIR. 
However, we observe in all formulations significant dissolution 
enhancement over crystalline FEL, which has a Q14.5min and DE14.5min of 
16.4% and 13%, respectively. Additionally, according to the Korsmeyer- 
Peppas model, the majority of the ternary dispersions exhibit a complex 
quasi-fickian diffusion mediated release mechanism, comprised of 
multiple mechanisms occurring concurrently and consequently. To 
further elucidate the release mechanisms observed, we constructed 
Higuchi profiles for the ternary amorphous dispersions. 
As, observed in Fig. 9, formulations containing 20 wt% SyA exhibit a 
3-step release pattern, whilst all other formulations exhibit a 2-step 
release pattern; collectively these may explain the poor correlation of 
the Higuchi model over the entire dissolution profile. Indeed, a 2-step 
release pattern from porous silica matrices have been observed by 
other researchers [64,65], which were ascribed to the release of drug 
molecules from the external silica surface, followed by a release from the 
pore structure, albeit in the current case this is further complicated by 
the presence of the organic polymer. Thus, a detailed analysis is pro-
vided in the succeeding paragraph. 
In the case of the formulations containing 20 wt% or 40 wt% SyB at a 
25 wt% drug load, 2-step release patterns, mediated by an initial 
accelerated release stage, followed by a retarded release stage, are 
evident. Based on our earlier observations and characterisations, we 
attribute this pattern to the predominant dissolution of FEL from the SOL 
matrix, of which the release rate in the initial stage retards with a 
decrease in the SOL concentration. At a 25 wt% drug load containing 40 
wt% SyA, an initial burst release of more than 80% of FEL is observed, of 
which, based on our earlier observations, the majority of the drug 
released, is from the external MPSI surface instead of the SOL matrix. 
This is followed by a slower release presumably from the restricted pore 
structure and/or from FEL-FEL hydrogen bonded clusters. For the 
formulation containing 20 wt% SyA at the same drug load, release 
patterns are characterised by a 3-step release. Of note herein is the slow 
drug release rate of the first stage (despite significant SOL surface 
enrichment), in comparison to all other formulations containing SyA. 
This finding correlates with our earlier explanation, where we proposed 
that SOL assumes a retarding effect, in which erosion of the SOL matrix 
from the particle surface is necessitated to expose silica surfaces 
enriched with FEL. For the SyC formulations at a 25 wt% drug load, 
slightly faster drug release in both the first and second stage of the 
Higuchi profiles are observed for 20 wt% SyC in comparison to 40 wt% 
SyC. The lower drug release rates observed for the latter formulation can 
be potentially ascribed to the elevated presence of FEL-FEL hydrogen 
bonded clusters and the nature of the particles formed. These particles 
exist as hard agglomerates with an outer shell of insoluble porous 
matrices fused together by a comparatively hydrophobic adhesive (FEL). 
Albeit ameliorated by the hydrophilicity of the SyC primary particles; 
disintegration of these hard agglomerates, penetration of the dissolution 
media, and release of drug molecules from subsequent layers may 
progress comparatively slower than the more prevalent polymer 
erosion/swelling mediated drug release for the 20 wt% SyC formula-
tions at the same drug load. 
Generally, for the high drug load formulations, release patterns 
observed can be ascribed to similar release mechanisms as those pre-
sented in the low drug load formulations. However, the release rates and 
extents of release are significantly impaired, likely as a result of 
increased loading into the pore structure and an increased hydrophobic 
character due to the presence of significant FEL-FEL hydrogen bonded 
clusters. As a result, for some of these formulations, a 100% release 
cannot be achieved over the time frame allowed for the dissolution ex-
periments. However, we also undertook drug recovery studies in 
Fig. 9. Higuchi profiles of ternary milled extrudates containing MPSI. *Represents formulations with a 25% drug load and **Represents formulations with a 50% 
drug load. 
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methanol (results not shown) to rule out the possibility of drug loads 
significantly lower than the theoretical composition. 
3.5. Stability studies 
PXRD and DSC results indicated that after 6 months storage of all 
formulation at 30% RH and 20 ◦C, Felodipine in all formulations 
remained stable in its amorphous state except for the formulation 
comprised of 40 wt% SyB with a 50 wt% drug load (Fig. 10). 
This formulation, although apparently PXRD amorphous, exhibited a 
small barely visible melt endotherm in the DSC thermogram. Based on 
our aFTIR investigations, this formulation presented the highest surface 
or near surface concentration of FEL-FEL clusters, which were most 
susceptible to structural reformation, leading to recrystallisation. 
Nonetheless, the stability of FEL for all drug loads was significantly 
enhanced through incorporation of any of the MPSI grades, given that 
unary extruded FEL presented diffraction peaks indicating recrystalli-
sation within 2 days of exposure to identical storage conditions. 
4. Conclusions 
This study evidenced the generation of powdered amorphous solid 
dispersions post hotmelt extrusion through the addition of MPSI to a 
traditional API-Polymer blend. However, the realisation of such was 
shown to be dependent on the MPSI grade employed and the bulk 
concentration of the MPSI within the formulation. The bulk density and 
pore size of the MPSI grades along with the dynamic viscosity of the 
MPSI and SOL appeared to play a critical role by limiting the extent of 
spreading of drug/polymer mixtures to particles within close proximity 
and by facilitating sorption into the pore structure more readily. As a 
result, an increase in the measured Tg, resulting in a positive deviation 
from the Tg predicted by the Gordon-Taylor equation, was observed for 
formulations containing 20 wt% SyA, 40 wt% SyA and 40 wt% SyC at 
the 25 wt% drug load. In contrast, all other formulations resulted in Tgs 
below the Tg predicted by the Gordon Taylor equation. However, the 
measured Tgs in these cases were generally above that of the binary FEL- 
SOL control formulation. Nonetheless, the importance of the organic 
polymer lies in interacting with API molecules which are not mono-
molecularly dispersed onto the external silica surface. The location of 
the API molecules (i.e., within the organic polymer matrix, on the in-
ternal/external surface of the MPSI or existent separately as clusters) 
were determined, along with the predominant surface concentration of 
the respective polymers, and these were shown to dictate the release rate 
and the extent of release observed within the time frame of the disso-
lution experiment. 
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Fig. 10. DSC and XRD thermograms of extrudates post milling after 6 months exposure to 30% RH and 20 ◦C and diffraction pattern and melt endotherm of as- 
received Felodpine (FEL). 
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